Couser R J, Ferrara T B, Falde B, Johnson K, Schilling C G, Hoekstra R E
Division of Neonatology, Minneapolis Children's Medical Center, Minnesota.
J Pediatr. 1992 Oct;121(4):591-6. doi: 10.1016/s0022-3476(05)81154-0.
We studied 50 preterm infants who had multiple or traumatic endotracheal intubations, or whose duration of endotracheal intubation was > or = to 14 days, and who were considered at high risk for airway edema. These infants were enrolled in a prospective, randomized, controlled clinical trial to assess whether prophylactic dexamethasone therapy would be effective in the prevention of postextubation stridor and respiratory distress. At study entry, both groups had similar weights, postnatal ages, methylxanthine use, ventilator settings, blood gas values, and pulmonary function test results (dynamic compliance, total respiratory resistance, tidal volume, peak-to-peak transpulmonary pressure, minute ventilation, and peak inspiratory and expiratory flow rates). Patients underwent blood gas studies, physical examinations, and pulmonary function testing at baseline (4 hours before extubation) and again 2 to 4 hours and 18 to 24 hours after extubation. Twenty-seven infants received dexamethasone, 0.25 mg/kg per dose, at baseline, and then every 8 hours for a total of three doses; 23 infants received saline solution at corresponding times. Eighteen to twenty-four hours after extubation, total pulmonary resistance increased by 225% from baseline in the control group compared with 33% in the dexamethasone group (p < 0.006), and the dexamethasone group had a greater tidal volume, a greater dynamic compliance, and a lower arterial carbon dioxide pressure. Of 23 control infants, 10 had postextubation stridor compared with 2 of 27 dexamethasone-treated patients (p < 0.006). Of the 23 control patients, 4 required reintubation compared with none of the treated group (p < 0.05). We conclude that the prophylactic use of corticosteroids for the prevention of postextubation stridor and respiratory distress is efficacious in low birth weight, high-risk preterm infants.
我们研究了50例早产婴儿,这些婴儿进行过多次或创伤性气管插管,或气管插管持续时间≥14天,且被认为有气道水肿的高风险。这些婴儿被纳入一项前瞻性、随机、对照临床试验,以评估预防性地塞米松治疗是否能有效预防拔管后喘鸣和呼吸窘迫。在研究开始时,两组婴儿在体重、出生后年龄、甲基黄嘌呤使用情况、呼吸机设置、血气值和肺功能测试结果(动态顺应性、总呼吸阻力、潮气量、峰-峰跨肺压、分钟通气量以及吸气和呼气峰值流速)方面相似。患者在基线时(拔管前4小时)、拔管后2至4小时以及18至24小时再次接受血气研究、体格检查和肺功能测试。27例婴儿在基线时接受地塞米松治疗,剂量为0.25mg/kg,然后每8小时一次,共三次;23例婴儿在相应时间接受生理盐水治疗。拔管后18至24小时,对照组总肺阻力较基线增加了225%,而地塞米松组增加了33%(p<0.006),地塞米松组潮气量更大、动态顺应性更高且动脉二氧化碳分压更低。23例对照组婴儿中,10例出现拔管后喘鸣,而27例接受地塞米松治疗的患者中有2例出现(p<0.006)。23例对照组患者中有4例需要再次插管,而治疗组无一例需要(p<0.05)。我们得出结论,预防性使用皮质类固醇预防拔管后喘鸣和呼吸窘迫在低出生体重、高风险的早产婴儿中是有效的。